

IN THE CLAIMS:

Please add new claim 34 as follows:

1. (Previously Presented) A pharmaceutical product comprising any one of the following combinations of therapeutic agents, as a combined preparation for simultaneous, separate or sequential use in the treatment of inflammatory or respiratory diseases for which administration of one or more of the therapeutic agents is indicated:

- (i) salmeterol, ciclesonide and tiotropium;
- (ii) formoterol, budesonide and ipratropium;
- (iii) formoterol, ciclesonide and tiotropium;
- (iv) formoterol, budesonide and oxitropium;
- (v) salbutamol, beclomethasone and ipratropium;
- (vi) salbutamol, budesonide and tiotropium;
- (vii) terbutaline, fluticasone and tiotropium;
- (viii) terbutaline, fluticasone and ipratropium;
- (ix) salbutamol, budesonide and ipratropium;
- (x) salmeterol, fluticasone and ipratropium;
- (xi) salmeterol, budesonide and ipratropium;
- (xii) salmeterol, fluticasone and tiotropium; and
- (xiii) formoterol, budesonide and tiotropium;

wherein the above therapeutic agents are provided in particulate form; and for the combinations (i)-(ix) and (xiii) individually having a particle size from nano-size up to about 12 μ m; and for the combinations (x)-(xii), approximately 95% of the active particles have a particle size of below 2.5 μ m, and the remaining particles have a particle size of between 2.5 and 5 μ m; and can optionally be present as a pharmaceutically acceptable salt

or ester thereof, or in enantiomerically pure form or as a racemic mixture.

2. (Previously Presented) A pharmaceutical product according to claim 1, which comprises any one of the following combinations of therapeutic agents:

- (i) salmeterol, ciclesonide and tiotropium bromide;
- (ii) formoterol, budesonide and ipratropium;
- (iii) formoterol, ciclesonide and tiotropium bromide;
- (iv) formoterol, budesonide and oxitropium;
- (v) salbutamol sulphate, beclomethasone and ipratropium;
- (vi) salbutamol sulphate, budesonide and tiotropium bromide;
- (vii) terbutaline sulphate, fluticasone and tiotropium bromide;
- (viii) terbutaline sulphate, fluticasone and ipratropium bromide;
- (ix) salbutamol sulphate, budesonide and ipratropium bromide;
- (x) salmeterol, fluticasone propionate and ipratropium bromide;
- (xi) salmeterol, budesonide and ipratropium bromide;
- (xii) salmeterol, fluticasone propionate and tiotropium bromide; and
- (xiii) formoterol, budesonide and tiotropium bromide.

3. (Previously Presented) A pharmaceutical composition comprising any one of the following combinations of therapeutic agents for use in the treatment of inflammatory or respiratory diseases:

- (i) salmeterol, ciclesonide and tiotropium;
- (ii) formoterol, budesonide and ipratropium;
- (iii) formoterol, ciclesonide and tiotropium;

- (iv) formoterol, budesonide and oxitropium;
- (v) salbutamol, beclomethasone and ipratropium;
- (vi) salbutamol, budesonide and tiotropium;
- (vii) terbutaline, fluticasone and tiotropium;
- (viii) terbutaline, fluticasone and ipratropium;
- (ix) salbutamol, budesonide and ipratropium;
- (x) salmeterol, fluticasone and ipratropium;
- (xi) salmeterol, budesonide and ipratropium;
- (xii) salmeterol, fluticasone and tiotropium; and
- (xiii) formoterol, budesonide and tiotropium;

wherein the above therapeutic agents are provided in particulate form ; and for the combinations (i)-(ix) and (xiii) individually having a particle size from nano-size up to about 12 μm ; and for the combinations (x)-(xii), approximately 95% of the active particles have a particle size of below 2.5 μm , and the remaining particles have a particle size of between 2.5 and 5 μm ; and can optionally be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture, together with a pharmaceutically acceptable carrier or excipient therefor.

4. (Previously Presented) A composition according to claim 3, which comprises any one of the following combinations of therapeutic agents:

- (i) salmeterol, ciclesonide and tiotropium bromide;
- (ii) formoterol, budesonide and ipratropium;
- (iii) formoterol, ciclesonide and tiotropium bromide;
- (iv) formoterol, budesonide and oxitropium;
- (v) salbutamol sulphate, beclomethasone and ipratropium;

- (vi) salbutamol sulphate, budesonide and tiotropium bromide;
- (vii) terbutaline sulphate, fluticasone and tiotropium bromide;
- (viii) terbutaline sulphate, fluticasone and ipratropium bromide;
- (ix) salbutamol sulphate, budesonide and ipratropium bromide;
- (x) salmeterol, fluticasone propionate and ipratropium bromide;
- (xi) salmeterol, budesonide and ipratropium bromide;
- (xii) salmeterol, fluticasone propionate and tiotropium bromide; and
- (xiii) formoterol, budesonide and tiotropium bromide.

5. (Previously Presented) A composition according to claim 3, wherein the anti-cholinergic of the composition is present in an amount 0.001wt% to 0.5wt% based on the weight of the total composition.

6. (Previously Presented) A composition according to claim 3, wherein the β -2 agonist of the composition is present in an amount 0.001wt% to 0.5wt% based on the weight of the total composition.

7. (Previously Presented) A composition according to claim 3, wherein the steroid of the composition is present in an amount 0.001wt% to 0.5wt% based on the weight of the total composition.

8. (Previously Presented) A composition according to claim 3, in a form suitable for administration by inhalation.

9. (Previously Presented) A composition according to claim 8, in the form of an aerosol.

10. (Cancelled)

11. (Cancelled)

12. (Cancelled)

13. (Cancelled)

14. (Cancelled)

15. (Previously Presented) A composition according to claim 9, which comprises any one of the following combinations of therapeutic agents:

- (i) salmeterol, ciclesonide and tiotropium;
- (ii) formoterol, budesonide and ipratropium;
- (iii) formoterol, ciclesonide and tiotropium;
- (iv) formoterol, budesonide and oxitropium;
- (v) salbutamol, beclomethasone and ipratropium;
- (vi) salbutamol, budesonide and tiotropium;
- (vii) terbutaline, fluticasone and tiotropium;
- (viii) salmeterol, fluticasone and tiotropium; and
- (ix) formoterol, budesonide and tiotropium;

wherein the above therapeutic agents can optionally be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.

16. (Previously Presented) A composition according to claim 15, which

comprises any one of the following combinations of therapeutic agents:

- (i) salmeterol, ciclesonide and tiotropium bromide;
- (ii) formoterol, budesonide and ipratropium;
- (iii) formoterol, ciclesonide and tiotropium bromide;
- (iv) formoterol, budesonide and oxitropium;
- (v) salbutamol sulphate, beclomethasone and ipratropium;
- (vi) salbutamol sulphate, budesonide and tiotropium bromide;
- (vii) terbutaline sulphate, fluticasone and tiotropium bromide;
- (viii) salmeterol, fluticasone propionate and tiotropium bromide; and
- (ix) formoterol, budesonide and tiotropium bromide.

17. (Previously Presented) A metered dose inhaler which contains a composition as defined in claim 9.

18. (Previously Presented) A composition according to claim 8, further comprising an excipient to form an inhalation powder.

19. (Previously Presented) A composition according to claim 18, which comprises lactose as the excipient.

20. (Previously Presented) A composition according to claim 18, which comprises any one of the following combinations of therapeutic agents:

- (i) salmeterol, ciclesonide and tiotropium;
- (ii) formoterol, budesonide and ipratropium;
- (iii) formoterol, ciclesonide and tiotropium;

- (iv) salbutamol, beclomethasone and ipratropium;
- (v) salbutamol, budesonide and tiotropium;
- (vi) terbutaline, fluticasone and tiotropium;
- (vii) salmeterol, fluticasone and tiotropium; and
- (viii) formoterol, budesonide and tiotropium;

wherein the above therapeutic agent can optionally be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.

21. (Previously Presented) A composition according to claim 20, which comprises any one of the following combinations of therapeutic agents:

- (i) salmeterol, ciclesonide and tiotropium bromide;
- (ii) formoterol, budesonide and ipratropium;
- (iii) formoterol, ciclesonide and tiotropium bromide;
- (iv) salbutamol sulphate, beclomethasone and ipratropium;
- (v) salbutamol sulphate, budesonide and tiotropium bromide;
- (vi) terbutaline sulphate, fluticasone and tiotropium bromide;
- (vii) salmeterol, fluticasone and tiotropium; and
- (viii) formoterol, budesonide and tiotropium.

22. (Previously Presented) A dry powder inhaler which contains a composition as defined in claim 18.

23. (Previously Presented) A composition according to claim 8, in the form of a propellant free inhalation solution or suspension.

24. (Previously Presented) A composition according to claim 23, which

comprises any one of the following combinations of therapeutic agents:

- (i) terbutaline, fluticasone and ipratropium;
- (ii) salbutamol, budesonide and ipratropium;
- (iii) salmeterol, fluticasone and ipratropium;
- (iv) salmeterol, budesonide and ipratropium;
- (v) salmeterol, fluticasone and tiotropium; and
- (vi) formoterol, budesonide and tiotropium;

wherein the above therapeutic agents can optionally be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.

25. (Previously Presented) A composition according to claim 24, which comprises any one of the following combinations of therapeutic agents:

- (i) terbutaline sulphate, fluticasone and ipratropium bromide;
- (ii) salbutamol sulphate, budesonide and ipratropium bromide;
- (iii) salmeterol, fluticasone propionate and ipratropium bromide;
- (iv) salmeterol, budesonide and ipratropium bromide;
- (v) salmeterol, fluticasone propionate and tiotropium bromide; and
- (vi) formoterol, budesonide and tiotropium bromide.

26. (Previously Presented) A composition according to claim 23, in a form suitable for use with a nebuliser.

27.-33. (Cancelled)

34. (New) A pharmaceutical product comprising any one of the following combinations of therapeutic agents, as a combined preparation for simultaneous, separate or sequential use in the treatment of inflammatory or respiratory diseases for which administration of one or more of the therapeutic agents is indicated:

- (i) salmeterol, ciclesonide and tiotropium;
- (ii) formoterol, budesonide and ipratropium;
- (iii) formoterol, ciclesonide and tiotropium;
- (iv) formoterol, budesonide and oxitropium;
- (v) salbutamol, beclomethasone and ipratropium;
- (vi) salbutamol, budesonide and tiotropium;
- (vii) terbutaline, fluticasone and tiotropium;
- (viii) terbutaline, fluticasone and ipratropium;
- (ix) salbutamol, budesonide and ipratropium;
- (x) salmeterol, fluticasone and ipratropium;
- (xi) salmeterol, budesonide and ipratropium;
- (xii) salmeterol, fluticasone and tiotropium; and
- (xiii) formoterol, budesonide and tiotropium;

wherein the above therapeutic agents (i)-(xii) are provided in particulate dosage form selected from the group consisting of a propellant- containing dosage aerosol, an inhalation powder and a propellant free inhalation suspension; and for the combinations (i)-(ix) and (xiii) individually having a particle size from nano-size up to about 12 μm ; and for the combinations (x)-(xii), approximately 95% of the active particles have a particle size of below 2.5 μm , and the remaining particles have a particle size of between 2.5 and 5 μm ; and can optionally be present as a pharmaceutically acceptable salt or ester thereof, or in enantiomerically pure form or as a racemic mixture.